

# Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

## CD4-FITC, mouse

RRID:AB\_2659902

Type: Antibody

---

### Proper Citation

Miltenyi Biotec Cat# 130-102-541, RRID:AB\_2659902

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2659902](http://antibodyregistry.org/AB_2659902)

**Proper Citation:** Miltenyi Biotec Cat# 130-102-541, RRID:AB\_2659902

**Target Antigen:** CD4

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Discontinued: 1-2019; Target Distribution dendritic cells, granulocytes, Langerhans cells, lymphocytes, macrophages, monocytes, neutrophils, T cells, T helper cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:30 µg in 1 mL

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-819. (RRID:AB\_2752205).

**Antibody Name:** CD4-FITC, mouse

**Description:** This monoclonal targets CD4

**Target Organism:** mouse

**Clone ID:** GK1.5

**Antibody ID:** AB\_2659902

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-102-541

**Record Creation Time:** 20231110T034401+0000

**Record Last Update:** 20260831T231345+0000

---

## Ratings and Alerts

No rating or validation information has been found for CD4-FITC, mouse.

**Warning:** Discontinued: 2021

Discontinued: 1-2019; Target Distribution dendritic cells, granulocytes, Langerhans cells, lymphocytes, macrophages, monocytes, neutrophils, T cells, T helper cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:30 µg in 1 mL  
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-819. (RRID:AB\_2752205).

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Krug A, et al. (2024) Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. Journal of experimental & clinical cancer research : CR, 43(1), 43.

Calvani M, et al. (2019) ?3 -Adrenoceptor as a potential immuno-suppressor agent in melanoma. British journal of pharmacology, 176(14), 2509.